YP2A Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - BioLine RX Ltd

Watchlist Manager

Watchlist

Price: 2.98 EUR

Market Cap: €238.2m

	BioLine RX Ltd F:YP2A	IL
S	Stellus Capital Investment Corp F:GO0	US
	Stellus Capital Investment Corp NYSE:SCM	US
P	Preferred Apartment Communities Inc F:P2A	US
P	Pixelworks Inc XMUN:PXLX	US
A	Avis Budget Group Inc XMUN:CUCA	US
A	Assurant Inc LSE:0HIN	US
P	Prudential PLC F:PRU2	UK
P	Prudential PLC SGX:K6S	UK
	Fresenius SE & Co KGaA XETRA:FRE	DE
	Innocan Pharma Corp F:IP40	IL

Profitability Summary

BioLine RX Ltd's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

81%

Strong 3Y Average Gross Margin

60%

Negative Operating Margin

-872%

Negative 3Y Average Operating Margin

-320%

Negative Net Margin

-172%

Negative 3Y Average Net Margin

-249%

Negative Free Cash Flow Margin

-687%

Negative 3Y Average Free Cash Flow Margin

-250%

Negative ROE

-13%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-207%

ROIC is Increasing

-205% > -81%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.